Stock Ratings / Health Care / SVRA / earnings

LTGO (55) MLTX (46) RIGL (74) JANX (33) ⌘ Pro Terminal →

Savara Inc. (SVRA) Next Earnings Date & Expected ±12.5% Move

$4.95 -1.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Savara Inc. (SVRA) carries a Roarable Rating of D- (Sell) with 43/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • SELL / AVOID Cap $1.02B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-6.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SVRA)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.62 Expected Swing

MODEL EARNINGS SETUP GAUGE

SVRA Quantitative Pre-Earnings Setup: 43/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (43/100)Model Risk Weight (57/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	-$118.8M	-$101.1M	52%
FY 2024	2024-12-31	$0	-$95.9M	-$89.1M	52%
FY 2023	2023-12-31	$0	-$54.7M	-$51.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SVRA)

✓Walkthrough of SVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.53%⚡ TESTING RESISTANCE

2026-10-30O $4.88H $4.97L $4.75C $4.95VOL 1.41M

RES: $5.11SUP: $4.03SMA50: $5.07SMA200: $5.39

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SVRA Butterfly Map → + Track SVRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SVRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SVRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SVRA)

Health Care Rank #545 of 1016 ⚔️ LTGO vs SVRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SVRA vs. LTGO, MLTX, RIGL, JANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Savara Inc. (SVRA) ranks #545 by composite RQD confidence (43/100, grade D-) and #359 by equity capitalization ($1.02B). Within this direct 5-issuer industry benchmark cohort, SVRA leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SVRA at 43/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SVRA ACTIVE Savara Inc.	D-	43/100	—	—	-35.0%	-1.39%	$1.02B	Benchmark Subject
LTGO Latigo Biotherapeutics Inc.	D+	55/100	—	—	—	-1.83%	$1.03B	/ltgo-vs-svra →
MLTX MoonLake Immunotherapeutics (Class A)	D	46/100	—	—	-35.0%	+2.11%	$1.07B	/mltx-vs-svra →
RIGL Rigel Pharmaceuticals Inc.	B	74/100	—	93.3%	28.2%	+1.40%	$961.1M	/rigl-vs-svra →
JANX Janux Therapeutics Inc.	E	33/100	—	—	-13.8%	-1.22%	$1.09B	/janx-vs-svra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001160308

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Savara Inc. (SVRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$118.8M, operating cash flow of -$101.0M, and free cash flow of -$101.1M (-13.4% YoY). On the balance sheet, SVRA closed FY2025 with $253.4M in total assets against $29.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$118.8M	-$101.0M	-$101.1M	$253.4M	$29.9M
FY2024 (FY)	2024-12-31	$0	-$95.9M	-$89.1M	-$89.1M	$212.9M	$26.6M
FY2023 (FY)	2023-12-31	$0	-$54.7M	-$51.1M	-$51.1M	—	—

3. SVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Savara Inc. (NASDAQ: SVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 43/100 at a spot price of $4.95 (-1.39% 1D, market cap $1.02B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SVRA ranks #545 in composite RQD confidence.

How does SVRA compare to LTGO and MLTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SVRA carries a Roarable D- (43/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LTGO (Latigo Biotherapeutics Inc.) holds a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $1.03B) and MLTX (MoonLake Immunotherapeutics (Class A)) posts a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B). Among the 5-stock peer group, SVRA leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SVRA?

Per SVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001160308), Savara Inc. generated $0 in revenue, -$118.8M in net income, and -$101.1M in free cash flow against $253.4M in total assets and $29.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SVRA trading relative to its 50-day, 200-day, and 52-week technical levels?

SVRA last traded at $4.95 (-1.39% on volume of 1,741,328 shares), positioning the stock -2.37% below its 50-day simple moving average ($5.07) and -8.16% below its 200-day simple moving average ($5.39). Across its 52-week range of $3.86 to $7.01, SVRA sits at the 34.6% percentile with a 14-day RSI of 49.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.33 to $5.57).